Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Towards a decentralized future for open-science databases.

Nature genetics·2026

Same author

Supportive oncology and the USA Cancer Moonshot: academic, clinical and operational opportunities.

BMJ supportive & palliative care·2026

Same author

From inflammation to precision medicine in colon cancer: Methodological considerations and future directions.

World journal of gastrointestinal surgery·2026

Same author

Prevalence and Correlates of Sleep Difficulties in a Large Multicenter Outpatient Oncology Population as Identified through Practice-Based Screening.

Cancer research communications·2026

Same author

Selective control of ligand binding through a distal mutation that alters the protein native ensemble.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same author

Extended aromatase inhibitor therapy for early breast cancer.

Lancet (London, England)·2026

Same journal

Clinical value of geriatric nutritional risk index and pan-immune-inflammation value in locally advanced gastric cancer receiving neoadjuvant chemotherapy.

World journal of gastrointestinal oncology·2026

Same journal

Recent advances in spasmolytic polypeptide expressing metaplasia research.

World journal of gastrointestinal oncology·2026

Same journal

Increasing expression of presenilin 1, β-catenin, and p-PTEN and its regulatory roles on cell invasion in gastric cancer.

World journal of gastrointestinal oncology·2026

Same journal

Advancing precision medicine in human epidermal growth factor receptor 2 negative gastric cancer: Insights from a novel nomogram for immunochemotherapy prognosis.

World journal of gastrointestinal oncology·2026

Same journal

Impact of liver metastasis on the efficacy of immune checkpoint inhibitors for advanced colorectal cancer.

World journal of gastrointestinal oncology·2026

Same journal

Computed tomography with carcinoembryonic antigen and carbohydrate antigen 19-9 in diagnosing lymph node metastasis of early gastric cancer.

World journal of gastrointestinal oncology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Optimizing fluoropyrimidine therapy through dihydropyrimidine dehydrogenase polymorphism testing.

Arunkumar Krishnan¹

¹Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC 28204, United States. dr.arunkumar.krishnan@gmail.com.

World Journal of Gastrointestinal Oncology

|June 9, 2025

Summary

This summary is machine-generated.

Pharmacogenetic testing for dihydropyrimidine dehydrogenase (DPYD) deficiency improves fluoropyrimidine (FP) cancer therapy safety. Further studies are needed to address limitations and integrate DPYD testing into clinical practice for better patient outcomes.

Area of Science:

Oncology
Pharmacogenetics
Clinical Medicine

Background:

Fluoropyrimidines (FP) are vital in solid tumor treatment but cause severe toxicity in 20-30% of patients.

Keywords:

Dihydropyrimidine dehydrogenase Drug adverse reactions Drug toxicity Economic evaluation Fluoropyrimidine Gastrointestinal cancers Genetic testing Polymorphisms

More Related Videos

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Published on: April 5, 2015

Related Experiment Videos

Last Updated: Jun 12, 2025

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Regioselective O-Glycosylation of Nucleosides via the Temporary 2',3'-Diol Protection by a Boronic Ester for the Synthesis of Disaccharide Nucleosides

Published on: July 26, 2018

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Rapid Identification of Chemical Genetic Interactions in Saccharomyces cerevisiae

Published on: April 5, 2015

Dihydropyrimidine dehydrogenase (DPYD) deficiency, identified via DPYD polymorphisms, is a key factor in FP toxicity.

Pharmacogenetic testing for DPYD variants has improved FP therapy safety by reducing adverse events.